Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 20/20 | 0.64 |
| ▸ | HTR2B | P41595 | 8/20 | 0.56 |
| ▸ | HTR2A | P28223 | 6/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4973397 | 1.00 | HTR2C (0.64) | HTR2CHTR2BHTR2A | |
| SCHEMBL4057434 | 1.00 | HTR2C (0.64) | HTR2CHTR2BHTR2A | |
| SCHEMBL4354532 | 1.00 | HTR2C (0.64) | HTR2CHTR2BHTR2A | |
| SCHEMBL4348100 | 0.79 | HTR2C (0.67) | HTR2CHTR2BHTR2A | |
| SCHEMBL7735978 | 0.79 | HTR2C (0.67) | HTR2CHTR2BHTR2A | |
| SCHEMBL4347966 | 0.79 | HTR2C (0.67) | HTR2CHTR2BHTR2A | |
| SCHEMBL16168362 | 0.79 | HTR2C (1.00) | HTR2CHTR2BHTR2A | |
| SCHEMBL20698202 | 0.79 | HTR2C (0.94) | HTR2CHTR2BHTR2A | |
| SCHEMBL7229772 | 0.79 | HTR2C (0.94) | HTR2CHTR2BHTR2A | |
| SCHEMBL29434863 | 0.79 | HTR2C (1.00) | HTR2CHTR2BHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090281091-A1 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2009-11-12 | — | — | US | claimed |
| EP-1998780-A2 | NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | Wyeth a Corporation of the State of Delaware (US) | 2008-12-10 | — | — | EP | claimed |
| US-20070238725-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | WYETH (US) | 2007-10-11 | — | — | US | claimed |
| WO-2007111983-A2 | NEW THERAPEUTIC COMBINATIONS FOR THE TREATMENT OR PREVENTION OF PSYCHOTIC DISORDERS | WYETH (US) | 2007-10-04 | — | — | WO | claimed |
| US-20070225279-A1 | Therapeutic combinations for the treatment of depression | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-20070225277-A1 | Treatment of pain | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-20070225278-A1 | Methods for treating cognitive and other disorders | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-20070225274-A1 | Methods for modulating bladder function | WYETH (US) | 2007-09-27 | — | — | US | claimed |
| US-20090281091-A1 | METHODS FOR MODULATING BLADDER FUNCTION | WYETH (US) | 2009-11-12 | — | — | US | disclosed |
| US-20080009480-A1 | CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2008-01-10 | — | — | US | disclosed |
| US-20080009480-A1 | CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | WYETH (US) | 2008-01-10 | — | — | US | disclosed |
| US-7271163-B2 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271163-B2 | Cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives | WYETH (US) | 2007-09-18 | — | — | US | disclosed |
| US-6777407-B2 | 7BH-CYCLOPENTA(B)(1,4)DIAZEPINO(6, 7, 1-HI)INDOLE OR A SALT, USEFUL FOR TREATMENT OF SCHIZOPHRENIA, OBSESSIVE COMPULSIVE DISORDER, DEPRESSION, ANXIETY, PANIC DISORDER, OBESITY OR EPILEPSY | WYETH | 2004-08-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238725-A1 | Therapeutic combinations for the treatment or prevention of psychotic disorders | SLC6A3, GRIN2A, GRIN2C | HTR2C 700/4885HTR2B 933/4885HTR2A 847/4885 |
| US-20090281091-A1 | METHODS FOR MODULATING BLADDER FUNCTION | PDE3A, PDE3B, PDE2A | HTR2C 1494/4885HTR2B 1580/4885HTR2A 1749/4885 |
| US-20070225279-A1 | Therapeutic combinations for the treatment of depression | BDNF, GRIN2A, GRIN3A | HTR2C 172/4885HTR2B 252/4885HTR2A 157/4885 |
| US-20070225277-A1 | Treatment of pain | OPRL1, OPRK1, OPRM1 | HTR2C 894/4885HTR2B 973/4885HTR2A 868/4885 |
| US-20070225274-A1 | Methods for modulating bladder function | PDE3A, PDE3B, PDE2A | HTR2C 1494/4885HTR2B 1580/4885HTR2A 1749/4885 |
| US-20070225278-A1 | Methods for treating cognitive and other disorders | CHAT, COMT, ACHE | HTR2C 25/4885HTR2B 69/4885HTR2A 31/4885 |
| US-20080009480-A1 | CYCLOPENTA[b][1,4]DIAZEPINO[6,7,1-hi]INDOLES AND DERIVATIVES | CNR1, HCRTR1, HTR3C | HTR2C 21/4885HTR2B 16/4885HTR2A 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.